Tag: neuroendocrine tumours

Neuroendocrine tumours (NETs) arise from neuroendocrine cells (NECs). NECs are defined as cells 1) with the ability to produce neurotransmitters, neuromodulators, or neuropeptide hormones, 2) containing dense core secretory granules, 3) and lacking axons and synapses [1]. Since NECs form some of the classic endocrine glands, tumours of parathyroids, adrenal medulla, and medullary thyroid cancer are sometimes also classified as NETs...

Chromogranin A (CgA) is a 49-kDa acidic glycoprotein [1]. CgA is physiologically released by exocytosis, and can be detected in blood [2, 3]. The first immunoassay for detection of circulating CgA levels in blood was a RIA method developed in1984 by O’Connor and Bernstein. In 1989, Dillen et al. developed an EIA method with enzyme-conjugated CgA...

Chromogranin A (CgA) is a 49-kDa hydrophilic glycoprotein composed of 439 aa. It is present in all normal and abnormal neuroendocrine cells [1, 2]. The CgA gene is located on the 14th chromosome. CgA is a major Ca²+ storage protein and can aggregate at high concentrations of calcium [3]. Chromogranin A belongs to the chromogranin/secretogranin family...

Neuroendocrine tumours (NETs) are a heterogeneous group of tumours originating from endocrine cells scattered throughout the body and which form the diffuse endocrine system. Functioning tumours produce hormones or catecholamines which are responsible for the characteristic clinical picture...

Oncological diseases are still a challenge to clinicians and inspire the search for new diagnostic and therapeutic procedures. Lately, radionuclide therapy with 90Y-labelled compounds has been introduced in the treatment of neuroendocrine tumours  (NET) and non-Hodgkin's lymphomas (NHL)...

Recently, dopamine D2 receptors (RD2) have been found to be expressed in neuroendocrine tumours (NET), the tumourswhich arise from the diffuse neuroendocrine cells. Moreover, successful trials of the treatment of NET with cabergoline — D2 agonist,have been reported. These findings increase the interest of investigating RD2 expression in NET....

The aim of this study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of the high affinity somatostatin receptor subtype 2 analogue, 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in neuroendocrine tumours (NETs)...

Chromogranina A (CgA, chromogranin A) jest powszechnie uznawana jako główny, niespecyficzny marker guzów neuroendokrynnych (NET, neuroendocrine tumours). Liczne czynniki i stany patologiczne mogą wpływać na stężenie CgA...

Guzy neuroendokrynne układu pokarmowego (GEP- -NET) stanowią heterogenną grupę guzów. Skuteczność dotychczas stosowanych metod terapeutycznych w GEP-NET jest ograniczona. Podstawową metodą leczenia tych nowotworów jest chirurgia. W farmakoterapii guzów GEP-NET stosuje się: bioterapię (analogi somatostatyny i interferon a), chemioterapię oraz terapię ukierunkowaną molekularnie (terapię celowaną)...